LEGN Legend Biotech
- 46.120
- +0.820+1.81%
Legend Biotech News
Legend Biotech | 6-K: Legend Biotech Announces EU Commission Approval of CARVYKTI for Second-Line Treatment in Patients with Relapsed or Refractory Multiple Myeloma
Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Legend Biotech | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(3.0%)
Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Legend Biotech | 144: Notice of proposed sale of securities pursuant to Rule 144
Legend Biotech | 144: Notice of proposed sale of securities pursuant to Rule 144
Legend Biotech | 144: Notice of proposed sale of securities pursuant to Rule 144
Legend Biotech | 144: Notice of proposed sale of securities pursuant to Rule 144
Legend Biotech | 144: Notice of proposed sale of securities pursuant to Rule 144
Legend Biotech | 144: Notice of proposed sale of securities pursuant to Rule 144
Legend Biotech | F-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers
Legend Biotech | 20-F: Registration statement / Annual report / Transition report
Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Legend Biotech | 6-K: Report of foreign private issuer (related to financial reporting)
Legend Biotech | 144: Notice of proposed sale of securities pursuant to Rule 144
Legend Biotech | 144/A: Others
Legend Biotech | 144: Notice of proposed sale of securities pursuant to Rule 144
Legend Biotech | 144: Notice of proposed sale of securities pursuant to Rule 144
Analysis
Price Target
No Data
